Sumitomo Pharma said on October 27 that its investigational oral small-molecule agent enzomenib has received breakthrough therapy designation from the US FDA for relapsed or refractory acute leukemia with KMT2A gene rearrangements. Enzomenib inhibits the interaction between menin and KMT2A…
To read the full story
Related Article
- Sumitomo Completes Enrollment for Enzomenib PII Analysis
June 11, 2026
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





